CUE241115P2000
- 0.45
- 0.000.00%
Cue Biopharma Newsroom
Cue Biopharma (NASDAQ:CUE) Adds US$31m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 89%
12 Health Care Stocks Moving In Monday's Intraday Session
Trevena TRVN -58% AH NASDAQ Delisting; Cue Biopharma CUE +42% SITC Presentation
Express News | Cue Biopharma Inc: Second Amendment Removes Requirement for Co to Maintain in Accounts of Svb Cash Equal to at Least $20 Mln
Express News | Cue Biopharma Inc: Enters Second Amendment to Loan Agreement With Svb
Cue Biopharma Stock Rallies Nearly 40% on Upcoming Presentations
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
Express News | Cue Biopharma Inc : Piper Sandler Cuts Target Price to $2 From $3
Cue Biopharma Shares Are Trading Higher. The Company Annonunced It Priced Its $12 Million Public Offering.
Express News | Cue Biopharma Shares Reverse Premarket Losses, Last up 9%
Cue Biopharma Offering Is Expected to Close Around Sept. 30 >CUE
12 Health Care Stocks Moving In Thursday's After-Market Session
Cue Biopharma Announces Common Stock, Warrant Offering, No Amount Given
Cue Biopharma Announces Proposed Public Offering
Express News | Cue Biopharma Announces Proposed Public Offering
Press Release: Cue Biopharma Announces Proposed Public Offering
Express News | Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
Press Release: Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
A Quick Look at Today's Ratings for Cue Biopharma(CUE.US), With a Forecast Between $2 to $6